Technologies

time icon June 7, 2012

Chemically Modified Curcumins (CMCs) Their Homolgues and Lower Analogues as Inhibitors of Matrix Metalloproteases (MMPs) and Pro-inflammatory Cytokkines (PICs)

Technology description

At Stony Brook University, two eminent researchers are working with new synthetic compounds to overcome curcumin’s disadvantages. The compounds are designed to be more soluble than natural curcumin which will enhance therapeutic efficacy, may improve pharmacokinetics, increase bio-availability and reduce cytotoxity.

Francis Johnson, Ph.D., professor in the Department of Chemistry and Pharmacological Sciences, and president of the custom synthesis and process development company, Chem-Masters International Inc., has synthesized a novel class of compound that displays biological activity that may be better than naturally-occurring curcumin. Working with these novel compounds, Dr. Lorne M. Golub, D.M.D., M.S.c., M.D. (Honorary), distinguished professor in the Department of Oral Biology and Pathology, has used them as zinc binding agents to modulate human MMP expression, production and activity, as well as aberrant pro-inflammatory cytokine expression and harmful growth factor activity. Their research shows promise as new treatment for connective tissue-and bone-destructive ailments, and inflammatory related diseases, including ARDS and rheumatoid arthritis.

由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。

More information

Categories
  • Information technology
  • Division of Rheumatology
Keywords:

stony brook university

overcome curcumin’s disadvantages

enhance therapeutic efficacy

process development company

zinc binding agents

下载 PDF 文档


感兴趣

Contact us

知繁业茂-yintrust logo知繁业茂-Branchly Innovation logo 知繁业茂-autmasia logo迈科技 logo